We conducted a blind and independent “voice of the customer” industry survey in late Q4 2020 and into early Q1 2021 with the opt-in online readership of Contract Pharma to ascertain what impact COVID-19 had and was continuing to have on outsourcing decisions for those who sought CRO, CDMO, or both CRO and CDMO services in the global pharmaceutical industry.
The insights provided by survey respondents reveal what happened within the outsourcing industry in 2020, where it’s going in 2021, and the role COVID-19 played in dramatically shifting attitudes, preferences and actions within the global pharmaceutical supply chain.
In part one of our series, we outline the market conditions at the onset of COVID-19, review the characteristics of our respondent profile, and provide an Executive Summary of the Top Line Takeaways for our survey as a whole.
Discover part two of the series here.
Discover part three of the series here.
Discover part four of the series here.